Tom3 schreef op 24 november 2019 16:49:
Editas heeft de behandeling van haar eerste LCA10 patiënt uitgesteld tot begin 2020. Op 25 juli 2019 werd de Brilliance trial gelanceerd. Aanvankelijk was de eerste dosering gepland in de 2e helft van 2019. Het gaat hier om een eerste ex-vivo toepassing van Crispr-Cas9. Editas heeft ook een Usher 2a programma. Wat dat betreft is ProQR een tamelijk risicovol aandeel:
seekingalpha.com/article/4305829-edit...Costa Sun
Hi, good morning. This is Costa Sun for Matthew Harrison. My first question is, can you explain a little bit what caused the timeline for the first dosing of EDIT-101 to be pushed back into 2020 from 2019?
Charlie Albright
Sure. This is a -- as you can appreciate, this is a rare, inherited retinal disease and as with all rare diseases accruing patients is challenging, particularly challenging since the entry criteria for this first patient is restricted because that’s the right thing to do. It has to be an adult with light perception only. And it's further complicated by challenges with the holidays. The patients typically need to bring a caregiver, need to arrive before the surgery and they can't fly for 10 days after the surgery. So the combination of those things has just made it complicated as we approach the holiday season.